Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$29.95
-9.4%
$30.00
$5.17
$39.50
$256.24M1.1999,047 shs955,364 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$4.86
+0.8%
$4.69
$4.01
$9.33
$79.92M1.32192,935 shs91,709 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$3.53
+3.8%
$4.00
$0.52
$5.92
$232.34M1.92810,262 shs5.16 million shs
ZimVie Inc. stock logo
ZIMV
ZimVie
$9.26
+2.9%
$8.99
$8.15
$22.40
$257.86M2.1193,738 shs276,887 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-9.35%-11.07%+8.44%-18.06%+2,994,999,900.00%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
+0.83%+2.75%+0.41%+1.89%-3.38%
Neuronetics, Inc. stock logo
STIM
Neuronetics
+3.82%+2.02%-8.31%-6.37%+104.05%
ZimVie Inc. stock logo
ZIMV
ZimVie
+2.89%+5.35%+5.23%-15.12%-49.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
1.9817 of 5 stars
3.63.00.00.02.50.00.0
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.5151 of 5 stars
3.32.00.00.03.31.70.6
ZimVie Inc. stock logo
ZIMV
ZimVie
2.4841 of 5 stars
3.33.00.00.02.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
0.00
N/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.25
Buy$11.67140.05% Upside
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.67
Moderate Buy$5.5055.81% Upside
ZimVie Inc. stock logo
ZIMV
ZimVie
2.67
Moderate Buy$16.3376.39% Upside

Current Analyst Ratings Breakdown

Latest SRTS, STIM, SNWV, and ZIMV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/15/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $10.00
4/10/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$16.00
4/9/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/9/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/4/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$32.63M7.86N/AN/A($1.49) per share-20.10
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$41.81M1.91$0.43 per share11.25$3.41 per share1.43
Neuronetics, Inc. stock logo
STIM
Neuronetics
$74.89M3.10N/AN/A$0.57 per share6.19
ZimVie Inc. stock logo
ZIMV
ZimVie
$449.75M0.57$1.86 per share4.99$13.83 per share0.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$31.37M-$4.56N/AN/A-89.86%N/A-145.76%N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M$0.1048.6021.13N/A4.56%3.34%3.00%8/6/2025 (Estimated)
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$43.71M-$1.31N/AN/AN/A-53.67%-174.15%-38.41%8/11/2025 (Estimated)
ZimVie Inc. stock logo
ZIMV
ZimVie
-$25.83M-$0.71N/AN/A-4.40%5.53%2.84%7/31/2025 (Estimated)

Latest SRTS, STIM, SNWV, and ZIMV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.04-$0.16-$0.20-$0.16$7.23 million$8.34 million
5/9/2025Q1 2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A-$0.66N/A-$0.66N/A$9.34 million
5/8/2025Q1 2025
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.21$0.27+$0.06-$0.05$113.10 million$112.00 million
5/6/2025Q1 2025
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.13-$0.21-$0.08-$0.21$29.07 million$31.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A
0.40
0.28
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
8.06
5.74
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.40
2.44
2.28
ZimVie Inc. stock logo
ZIMV
ZimVie
0.58
2.14
1.48

Institutional Ownership

CompanyInstitutional Ownership
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
42.53%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%
ZimVie Inc. stock logo
ZIMV
ZimVie
95.63%

Insider Ownership

CompanyInsider Ownership
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
36.60%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
8.90%
Neuronetics, Inc. stock logo
STIM
Neuronetics
8.70%
ZimVie Inc. stock logo
ZIMV
ZimVie
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
408.56 million5.43 millionN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.44 million14.98 millionOptionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
18065.82 million60.09 millionOptionable
ZimVie Inc. stock logo
ZIMV
ZimVie
1,77027.85 million27.01 millionOptionable

Recent News About These Companies

ZimVie: Screening Cheap (Rating Upgrade)
ZimVie Inc. (ZIMV) Q1 2025 Earnings Call Transcript
ZimVie Reports First Quarter 2025 Financial Results
Q1 2025 ZimVie Inc Earnings Call
ZimVie announces launch of its Immediate Molar Implant system in US
ZimVie launches molar implant system
Needham Remains a Hold on ZimVie Inc (ZIMV)
ZimVie initiated with a Buy at B. Riley

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Sanuwave Health stock logo

Sanuwave Health NASDAQ:SNWV

$29.95 -3.09 (-9.35%)
As of 06/27/2025 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$4.86 +0.04 (+0.83%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$4.73 -0.13 (-2.76%)
As of 06/27/2025 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

Neuronetics stock logo

Neuronetics NASDAQ:STIM

$3.53 +0.13 (+3.82%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$3.52 -0.01 (-0.28%)
As of 06/27/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

ZimVie stock logo

ZimVie NASDAQ:ZIMV

$9.26 +0.26 (+2.89%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$9.27 +0.01 (+0.11%)
As of 06/27/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.